AUSTIN, Texas and TOKYO, Oct. 1, 2025 /PRNewswire/ -- According to DataM Intelligence, The Bioresorbable Implants Market Size was US$ 7.00 billion in 2024 and is projected to grow to US$ 14.34 billion by 2033, expanding at a CAGR of 7.4% between 2025 and 2033. The Bioresorbable Implants Market is transforming surgical care by eliminating the need for permanent implants.
The shift from traditional metallic implants to bioresorbable alternatives reflects a broader healthcare transformation toward patient safety, reduced complications, and cost efficiency. Unlike conventional devices that require revision surgeries, bioresorbable implants gradually dissolve, leaving behind healthy tissue and lowering long-term risks. This innovation is not just a product upgrade-it is a paradigm shift in orthopedics, cardiology, and minimally invasive surgery.
Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/bioresorbable-implants-market
Browse in-depth TOC on "Bioresorbable Implants Market"
45 - Tables
46 - Figures
180 - Pages
Market Segmentation - Growth Anchors
By Material Type
In 2024, polymer-based implants dominated with 60% of total revenues (US$ 4.2 billion). Among them, PLLA (Poly L-lactide) accounted for the largest share, widely used in orthopedic fixation. PLGA and PGA implants are gaining traction in cardiovascular applications where controlled degradation is critical. Metallic bioresorbables, although smaller (US$ 1.5 billion in 2024), are emerging fast with magnesium-based implants showing strong clinical promise.
By Application
Orthopedics generated US$ 3.8 billion in 2024, fueled by sports injury treatments, trauma fixation, and pediatric orthopedics. Bioresorbable screws, pins, and plates are becoming the standard in ACL reconstruction and fracture repair.
Cardiovascular applications contributed US$ 2.5 billion, led by bioresorbable stents. With rising cases of coronary artery disease, these stents are gaining market traction due to lower risk of late thrombosis.
By End-User
Hospitals accounted for over 65% of revenues in 2024 (US$ 4.6 billion), reflecting their central role in advanced surgical procedures. Ambulatory Surgical Centers (ASCs), valued at US$ 1.8 billion, are growing rapidly as minimally invasive surgeries shift toward outpatient settings.
Regional Insights: USA & Japan
United States
The U.S., valued at US$ 2.8 billion in 2024, leads the market due to:
- High incidence of orthopedic and cardiovascular surgeries (over 1.5 million annually).
- Strong regulatory momentum, with FDA fast-tracking bioresorbable devices showing superior safety profiles.
- Recent update (2025): Johnson & Johnson's DePuy Synthes launched a new line of bioresorbable orthopedic fixation devices, gaining rapid adoption across trauma centers.
Japan
Japan's market, valued at US$ 0.6 billion in 2024, is expanding rapidly. Growth is supported by:
- Aging population driving demand for fracture fixation and cardiovascular interventions.
- PMDA approvals of bioresorbable magnesium implants in 2025.
- Strong collaborations between Stryker, Evonik, and Japanese surgical hospitals to integrate polymer-based bioresorbables in orthopedic practices.
Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/bioresorbable-implants-market
Industry Trends & 2025 Developments
- Next-Gen Materials: Magnesium- and zinc-based metallic bioresorbables are entering late-stage trials, promising faster healing and tailored degradation rates.
- 3D-Printed Implants: Hospitals in the U.S. and Japan are adopting 3D printing to customize bioresorbable implants for patient-specific anatomies.
- M&A Wave: In 2025, Stryker acquired a European polymer startup specializing in next-gen bioresorbable plates, strengthening its leadership in orthopedics.
- Digital Integration: Surgical navigation systems are being combined with bioresorbable implants for precision placement, reducing revision risks.
Competitive Landscape: Leaders Driving the Future
Stryker Corporation
Stryker remains at the forefront with US$ 1.3 billion revenues in bioresorbable implants in 2024. Its innovations in trauma fixation and sports medicine products continue to dominate the orthopedic landscape.
Johnson & Johnson (DePuy Synthes)
Johnson & Johnson generated US$ 1.1 billion in 2024, expanding aggressively into cardiovascular and orthopedic implants. The 2025 launch of advanced PLLA-based fixation systems reinforced its strong U.S. market presence.
Bioretec Ltd
Bioretec is a rising leader with pioneering magnesium-based implants. In 2025, it secured FDA clearance for its RemeOs trauma fixation system, marking a milestone in metallic bioresorbables.
Zimmer Biomet & Smith+Nephew
Both companies are scaling polymer implant portfolios with a focus on sports injuries and pediatric applications. Combined, they generated US$ 1.6 billion in 2024.
Evonik Industries AG
Evonik plays a key role as a material innovator, supplying polymers (Resomer® range) that power multiple bioresorbable implant lines across the industry.
Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=bioresorbable-implants-market
Strategic Outlook
The Bioresorbable Implants Market is entering its most transformative phase. Four key forces will define its trajectory:
- Material Innovation - Magnesium, zinc, and hybrid bioresorbables will set new clinical standards.
- Minimally Invasive Surgery Growth - ASCs and outpatient centers will drive accessibility and adoption.
- Regulatory Acceleration - Faster approvals in the U.S. and Japan will strengthen investor confidence.
- Shift to Value-Based Care - Cost efficiency, reduced complications, and improved patient outcomes will push hospitals to adopt bioresorbables at scale.
Conclusion
The Bioresorbable Implants Market, projected to rise from US$ 7.00 billion in 2024 to US$ 14.34 billion by 2033, is no longer a niche-it is the future of surgical implants. With the U.S. leading clinical adoption and Japan setting benchmarks in innovation, the sector offers compelling opportunities for hospitals, device manufacturers, and investors.
Related Report:
- Medical Implants Market Size to Hit USD 224.9 B by 2033 on Innovation in Smart, Biocompatible & 3D-Printed Devices.
- Breast Implants Market Size Set to Double by 2033: Innovation in Materials & Rising Reconstructive Demand Drive USD 5.2B Future.
- Dental Implants Market Size to More Than Double - From US$ 5.28B in 2024 to Over US$ 10B by 2033.
- Retinal Implants Market Size to Rise from USD 59M in 2022 to USD 118M by 2031: Vision-Restoring Tech Gains Traction.
About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com/
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/bioresorbable-implants-market-to-double-hitting-us-14-34-billion-by-2033-as-orthopedics-and-cardiovascular-applications-redefine-surgical-outcomes--by-datam-intelligence-302572336.html
